Jay S. Duker - Jan 5, 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
President and CEO, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Jan 5, 2024
Transactions value $
-$133,171
Form type
4
Date filed
1/9/2024, 09:07 PM
Previous filing
Jul 12, 2023
Next filing
Feb 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +20.8K +71.16% $0.00 50K Jan 6, 2024 Direct
transaction EYPT Common Stock Tax liability -$133K -6.53K -13.05% $20.40 43.5K Jan 6, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Award $0 +90K $0.00 90K Jan 5, 2024 Common Stock 90K $0.00 Direct F2
transaction EYPT Stock Option (Right to Buy) Award $0 +180K $0.00 180K Jan 5, 2024 Common Stock 180K $20.40 Direct F3
transaction EYPT Restricted Stock Units Options Exercise $0 -20.8K -33.33% $0.00 41.6K Jan 6, 2024 Common Stock 20.8K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2 The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.
F3 The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years.
F4 The restricted stock units vests in three ratable annual installments beginning January 6, 2024.